Breaking News, Collaborations & Alliances

argenx, Janssen Enter $1.6B Cancer Drug Deal

Collaboration to develop cusatuzumab in AML, MDS and other hematological malignancies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

argenx, a clinical stage biotech, has entered an exclusive, global collaboration and license agreement for cusatuzumab (ARGX-110), an anti-CD70 SIMPLE AntibodyÔ, with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson.     Cusatuzumab is currently in development in a Phase 1/2 combination study with Vidaza for newly diagnosed, elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) who are unfit for ch...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters